卵巢癌研究中对患者报告结果的积极评估:系统综述与未来研究行动呼吁。

IF 4.1 2区 医学 Q1 OBSTETRICS & GYNECOLOGY International Journal of Gynecological Cancer Pub Date : 2024-10-08 DOI:10.1136/ijgc-2024-005883
Ainhoa Madariaga, Rodrigo Sánchez-Bayona, Lawrence Kasherman, Jose Manuel Estrada-Lorenzo, Luis Manso, Pablo Tolosa, Manuel Alva, Laura Lema, Cristina González-Deza, Eva Ciruelos, David Valcarcel, Stephanie Lheureux, Amit M Oza
{"title":"卵巢癌研究中对患者报告结果的积极评估:系统综述与未来研究行动呼吁。","authors":"Ainhoa Madariaga, Rodrigo Sánchez-Bayona, Lawrence Kasherman, Jose Manuel Estrada-Lorenzo, Luis Manso, Pablo Tolosa, Manuel Alva, Laura Lema, Cristina González-Deza, Eva Ciruelos, David Valcarcel, Stephanie Lheureux, Amit M Oza","doi":"10.1136/ijgc-2024-005883","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This systematic review aims to evaluate the proactive or real-time assessment of patient reported outcomes in studies involving patients with ovarian cancer undergoing systemic therapy.</p><p><strong>Methods: </strong>PubMed, Embase, and Cochrane databases were searched (from database inception until February 2022), and prospective ovarian cancer studies (experimental or observational) that incorporated patient reported outcomes, including quality of life, were included. The primary objective was to assess the ratio of studies incorporating real-time use of patient reported outcomes among those studies performing patient reported outcomes. A secondary objective was to describe the patient reported outcome reporting. The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 checklist was followed. Descriptive statistics were used.</p><p><strong>Results: </strong>3071 articles were screened, with 117 included in the final analysis. Studies were published between 1990 and 2022, and consisted of 35 735 patients (median 140 patients per study; interquartile range 58-415). Median time from patient enrollment initiation to study publication was 7 years (range 1-15). Most studies were experimental/clinical trials (n=93, 79%) followed by observational (n=23, 20%). Therapeutic strategies were assessed in 98% (91/93) of experimental studies, most frequently chemotherapy (n=53, 58%), followed by antiangiogenics or poly-ADP ribose polymerase (PARP) inhibitors (n=8, 9%, each). Patient reported outcomes were the primary endpoint in 7.5% (7/93) and 83% (19/23) of experimental and observational studies, respectively. The ratio of real-time patient reported outcomes assessment/evaluation was 0.9% (1/117).</p><p><strong>Conclusions: </strong>Completion of patient reported outcome questionnaires involves time and effort for patients with ovarian cancer. Responses to these questionnaires were only assessed in real time in <1% of analyzed studies. Efforts should be made to incorporate proactive assessment of patient reported outcomes to optimize patient care and safety.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Proactive assessment of patient reported outcomes in ovarian cancer studies: a systematic review and call for action in future studies.\",\"authors\":\"Ainhoa Madariaga, Rodrigo Sánchez-Bayona, Lawrence Kasherman, Jose Manuel Estrada-Lorenzo, Luis Manso, Pablo Tolosa, Manuel Alva, Laura Lema, Cristina González-Deza, Eva Ciruelos, David Valcarcel, Stephanie Lheureux, Amit M Oza\",\"doi\":\"10.1136/ijgc-2024-005883\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This systematic review aims to evaluate the proactive or real-time assessment of patient reported outcomes in studies involving patients with ovarian cancer undergoing systemic therapy.</p><p><strong>Methods: </strong>PubMed, Embase, and Cochrane databases were searched (from database inception until February 2022), and prospective ovarian cancer studies (experimental or observational) that incorporated patient reported outcomes, including quality of life, were included. The primary objective was to assess the ratio of studies incorporating real-time use of patient reported outcomes among those studies performing patient reported outcomes. A secondary objective was to describe the patient reported outcome reporting. The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 checklist was followed. Descriptive statistics were used.</p><p><strong>Results: </strong>3071 articles were screened, with 117 included in the final analysis. Studies were published between 1990 and 2022, and consisted of 35 735 patients (median 140 patients per study; interquartile range 58-415). Median time from patient enrollment initiation to study publication was 7 years (range 1-15). Most studies were experimental/clinical trials (n=93, 79%) followed by observational (n=23, 20%). Therapeutic strategies were assessed in 98% (91/93) of experimental studies, most frequently chemotherapy (n=53, 58%), followed by antiangiogenics or poly-ADP ribose polymerase (PARP) inhibitors (n=8, 9%, each). Patient reported outcomes were the primary endpoint in 7.5% (7/93) and 83% (19/23) of experimental and observational studies, respectively. The ratio of real-time patient reported outcomes assessment/evaluation was 0.9% (1/117).</p><p><strong>Conclusions: </strong>Completion of patient reported outcome questionnaires involves time and effort for patients with ovarian cancer. Responses to these questionnaires were only assessed in real time in <1% of analyzed studies. Efforts should be made to incorporate proactive assessment of patient reported outcomes to optimize patient care and safety.</p>\",\"PeriodicalId\":14097,\"journal\":{\"name\":\"International Journal of Gynecological Cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Gynecological Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-005883\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Gynecological Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-005883","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的本系统综述旨在评估在涉及接受系统治疗的卵巢癌患者的研究中对患者报告结果的主动或实时评估:方法:检索了PubMed、Embase和Cochrane数据库(从数据库建立之初到2022年2月),纳入了包括生活质量在内的患者报告结果的前瞻性卵巢癌研究(实验性或观察性)。首要目标是评估在进行患者报告结果的研究中纳入实时使用患者报告结果的研究比例。次要目标是描述患者报告的结果报告。研究遵循了 "系统性综述和元分析首选报告项目"(Preferred Reporting Items for Systematic Review and Meta-Analyses,PRISMA)2020清单。结果共筛选出 3071 篇文章,其中 117 篇纳入最终分析。研究发表于 1990 年至 2022 年之间,共有 35 735 名患者(每项研究的中位数为 140 名患者;四分位数范围为 58-415 名)。从患者入组开始到研究发表的中位时间为 7 年(1-15 年不等)。大多数研究为实验/临床试验(93人,占79%),其次为观察性研究(23人,占20%)。98%(91/93)的实验研究对治疗策略进行了评估,其中最常见的是化疗(53人,占58%),其次是抗血管生成素或聚ADP核糖聚合酶(PARP)抑制剂(8人,各占9%)。在实验性研究和观察性研究中,分别有7.5%(7/93)和83%(19/23)的研究以患者报告的结果为主要终点。实时患者报告结果评估/评价的比例为 0.9%(1/117):结论:卵巢癌患者填写患者报告结果问卷需要花费时间和精力。只有在以下情况下才能对这些问卷的回复进行实时评估
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Proactive assessment of patient reported outcomes in ovarian cancer studies: a systematic review and call for action in future studies.

Objective: This systematic review aims to evaluate the proactive or real-time assessment of patient reported outcomes in studies involving patients with ovarian cancer undergoing systemic therapy.

Methods: PubMed, Embase, and Cochrane databases were searched (from database inception until February 2022), and prospective ovarian cancer studies (experimental or observational) that incorporated patient reported outcomes, including quality of life, were included. The primary objective was to assess the ratio of studies incorporating real-time use of patient reported outcomes among those studies performing patient reported outcomes. A secondary objective was to describe the patient reported outcome reporting. The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 checklist was followed. Descriptive statistics were used.

Results: 3071 articles were screened, with 117 included in the final analysis. Studies were published between 1990 and 2022, and consisted of 35 735 patients (median 140 patients per study; interquartile range 58-415). Median time from patient enrollment initiation to study publication was 7 years (range 1-15). Most studies were experimental/clinical trials (n=93, 79%) followed by observational (n=23, 20%). Therapeutic strategies were assessed in 98% (91/93) of experimental studies, most frequently chemotherapy (n=53, 58%), followed by antiangiogenics or poly-ADP ribose polymerase (PARP) inhibitors (n=8, 9%, each). Patient reported outcomes were the primary endpoint in 7.5% (7/93) and 83% (19/23) of experimental and observational studies, respectively. The ratio of real-time patient reported outcomes assessment/evaluation was 0.9% (1/117).

Conclusions: Completion of patient reported outcome questionnaires involves time and effort for patients with ovarian cancer. Responses to these questionnaires were only assessed in real time in <1% of analyzed studies. Efforts should be made to incorporate proactive assessment of patient reported outcomes to optimize patient care and safety.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.60
自引率
10.40%
发文量
280
审稿时长
3-6 weeks
期刊介绍: The International Journal of Gynecological Cancer, the official journal of the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of gynecologic malignancies. IJGC emphasizes a multidisciplinary approach, and includes original research, reviews, and video articles. The audience consists of gynecologists, medical oncologists, radiation oncologists, radiologists, pathologists, and research scientists with a special interest in gynecological oncology.
期刊最新文献
TERT promoter mutations and survival outcomes in adult-type granulosa cell tumors. The prognostic value of tumor-infiltrating lymphocytes in vulvovaginal melanoma. First robotic radical trachelectomy for cervical cancer using the Hugo RAS platform. Secondary cytoreductive surgery for recurrent endometrial cancer: can we predict the future? Mixed neuroendocrine and endometrioid carcinoma of the endometrium: a rare aggressive malignancy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1